A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Clinical trial NCT04144517 · COMPLETED

Trial details

NCT number: NCT04144517
Sponsor: Mural Oncology, Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck

Start date: 2020-02-05
Primary completion: 2021-10-08
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.